MANHASSET, N.Y.–(BUSINESS WIRE)–To continue its groundbreaking bipolar disorder research, Northwell Health’s The Feinstein Institutes for Medical Research has been awarded $2.3 million and joined the Breakthrough Discoveries for Thriving with Bipolar Disorder (BD²) Integrated Network, a national collaborative research and clinical care initiative aimed at transforming treatment and care for people living with bipolar disorder. … [Read more…]

PHILADELPHIA–(BUSINESS WIRE)–Holding product mix constant, Blue Cross Blue Shield Plans’ per member costs grew by 4.0% in 2024 compared with 5.6% in 2023 and 8.7% in 2022. The growth in Medicare Advantage and decline in Medicaid led to as-reported growth of 6.6%, compared with 5.9% in 2023. Median PMPM costs for all reporting Plans were … [Read more…]

BOSTON–(BUSINESS WIRE)–The Annual General Meeting of PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech Health” or the “Company”) was held at 11 a.m. EDT/4 p.m. BST on Monday, June 16, 2025. All of the resolutions proposed at the Annual General Meeting were duly passed by the shareholders on a poll. The results of the poll, … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Genetic Testing Markets. Global Market Analysis with Forecasts by Applications, Technologies, Products and Users with Executive and Consultant Guides” has been added to ResearchAndMarkets.com’s offering. The genetic testing industry is experiencing unprecedented growth, with its potential proving boundless as it expands across various sectors. This growth is being propelled by advancements in our … [Read more…]

–Real-world data highlight significant challenges with LTP adherence, and ongoing reliance on on-demand medications– –In KONFIDENT-S, oral sebetralstat delivered rapid, consistent relief for breakthrough attacks, regardless of long-term prophylaxis mechanism of action– CAMBRIDGE, Mass. & SALISBURY, England–(BUSINESS WIRE)–KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the presentation of new data at the European Academy of Allergy … [Read more…]

– Results from Phase IIb PADOVA and longer term follow-up data suggest clinical benefit on top of symptomatic treatment in early-stage Parkinson’s disease – – Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody, targeting a known biological driver of Parkinson’s disease progression – – Parkinson’s disease affects over 10 million people globally and significant unmet need … [Read more…]

~~Accelerating Access to Innovative Therapies in Japan through Alfresa Group’s ‘Total Supply Chain Service’~~ TOKYO–(BUSINESS WIRE)–HekaBio K.K. (Headquarters: Chuo-ku, Tokyo; President & CEO: Robert E. Claar; hereinafter “HekaBio”) today announced the signing of a strategic partnership agreement with Alfresa Holdings Corporation (Headquarters: Chiyoda-ku, Tokyo; Representative Director & President: Ryuji Arakawa; hereinafter “Alfresa Holdings”), the leading … [Read more…]

Results from the EPCORE® NHL-2 trial show investigational treatment with epcoritamab in combination with rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) led to an overall response rate (ORR) of 87 percent and a complete response (CR) rate of 65 percent in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) Data further demonstrates the … [Read more…]

QIAGEN to create a multimodal panel using next-generation sequencing (NGS) technology for detecting clinically relevant gene alterations in hematological malignancies Companion diagnostic to identify key disease-causing mutations in patients with MPNs, with an initial focus on mutant CALR the second most common driver of MPNs Panel to be validated on Illumina NextSeq 550Dx platform for … [Read more…]

TORONTO–(BUSINESS WIRE)–#CUPE–The union representing striking workers at the Workplace Safety and Insurance Board (WSIB) has conducted a follow-up survey to assess workload and occupational stress levels, one year after their initial study. The internationally recognized survey, conducted by the Occupational Health Clinics for Ontario Workers (OHCOW), an independent third party, shows that WSIB workers continue … [Read more…]